Risikostratifizierung mit Gen-Assay lohnt sich bei resezierbarem NSCLC

Im Focus Onkologie 2026

View at publisher
Authors: Thomas Müller
DOI: 10.1007/s15015-026-4510-4
Cited by: 0

Fields of Study & Subjects

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Breast Cancer Treatment Studies

Publication details

Journal / source
Im Focus Onkologie
Volume
29
Issue
1-2
Pages
53–53
Publication date
1 February 2026
Language
DE